LABORATORIO REIG JOFRE S.A. (ES:RJF)
BME:RJF
Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.40
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€221.33M
Enterprise Value€315.17M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)16.8
Beta0.31
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.11
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)€349.90M
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelRJF’s dual model—branded pharmaceutical sales plus CDMO/CMO manufacturing—creates structurally diversified revenue streams. Durable multi-year supply agreements and fee-based manufacturing reduce dependence on any single product, supporting steadier cash inflows and multiple growth levers over 2–6 months.
Pre-2025 Revenue And Margin Track RecordA multi-year trend of revenue growth and stable ~10–11% EBITDA margins through 2024 shows operational capability and scalable manufacturing economics. This historical performance indicates underlying competitiveness and cost control that could support margin recovery if the 2025 shock proves cyclical.
Moderate Historical Leverage And Equity BaseA history of moderate leverage and a gradually growing equity base gives the company financial flexibility. Prior lower debt levels mean capacity to absorb temporary stress, access credit for capex or working capital, and avoid aggressive restructuring if cash flows normalize.
Bears Say
Sharp 2025 Revenue And Margin DeclineA sudden 20% revenue drop with margins collapsing to ~1.7% signals loss of scale, pricing or demand pressures, and impaired operating leverage. Such structural earnings damage reduces internal funding, risks contract renegotiations, and could take multiple quarters to reverse without new product wins or additional contract volumes.
Severe Cash Flow WeaknessNegative free cash flow of ~-€13.8M and near-zero operating cash flow materially erode the company’s ability to self-fund capex, R&D, or dividends. With a history of cash volatility, sustained FCF weakness increases refinancing and liquidity risk and may force asset sales or external financing at unfavorable terms.
Rising Leverage With Weak ReturnsDebt-to-equity rising to ~0.45 while ROE falls to ~2.3% tightens the margin for error: servicing higher debt with weak returns strains cash flow and reduces strategic optionality. If margins and cash generation don’t recover, leverage amplifies solvency and investment risks over the medium term.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.40 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €221.33M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Jul 31, 2026 which is in 72 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
Currently, no data Available
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.049 which represents an annual dividend yield of 1.91%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Options Prices
Currently, No data available
---